Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis – Study 2
- 05 Septembre 2024 - 1 mn de lecture
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).
05 Septembre 2024
1 mn de lecture
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
05 Septembre 2024
1 mn de lecture
Equivalence of Intramuscular (IM) Versus Subcutaneous (SC) Applications of Long Acting Pamorelin 11.25 mg
05 Septembre 2024
1 mn de lecture
Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients
05 Septembre 2024
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.
05 Septembre 2024
1 mn de lecture
Quality of Life in Patients With Inoperable Malignant Bowel Obstruction
05 Septembre 2024
1 mn de lecture
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
05 Septembre 2024
1 mn de lecture
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
05 Septembre 2024
1 mn de lecture
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
05 Septembre 2024
1 mn de lecture
Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer
05 Septembre 2024
1 mn de lecture